<DOC>
	<DOCNO>NCT00582816</DOCNO>
	<brief_summary>This study assess feasibility utilize reduce intensity condition regimen , set haploidentical transplantation , patient recurrent acute lymphoblastic leukemia ( ALL ) , AML high risk refractory solid tumor . In addition , feasibility safety administer post-transplant NK cell infusion evaluate . Data obtain study help determine efficacy allogeneic HSCT treatment pediatric sarcoma add small body literature utilizing haploidentical HSCT treat acute leukemia pediatric patient . This study also elucidate role NK cell mediate graft vs. tumor effect allogeneic HSCT . The main benefit society study explore novel therapy child highly refractory cancer felt incurable conventional approach . If feasibility demonstrate , evidence anti-tumor activity , open new area clinical research well define efficacy approach specific childhood malignancy .</brief_summary>
	<brief_title>Haploidentical Transplant With NK Cell Infusion Pediatric Acute Leukemia Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<criteria>Solid tumor fail auto transplant ineligible receive auto transplant Relapsed AML 1st relapse 2nd 3rd CR Relapsed ALL fail attain initial remission relapse within 1 year follow discontinuation chemotherapy . Greater equal 6 month &lt; 26 year old Suitable haploidentical donor available Leukemia &gt; 25 % blast bone marrow time admission HSCT unit . Serum bilirubin &gt; 3 mg/dl GFR &lt; 40 ml/min/1.73 mw Cardiac leave ventricular ejection fraction &lt; 40 % HIV+ Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Recurrent Refractory Leukemia Solid Tumors Pediatrics</keyword>
</DOC>